Sixth Annual Targeted Therapies for the Treatment of Lung Cancer Conference

The CBCE
Last Modified: December 18, 2005

Conference Dates: January 26, 2006
Conference Location: Santa Monica, CA

Sponsoring Group: The Center for Biomedical Continuing Education

Conference Web Page URL: www.thecbce.com/currentactivities.asp

Topics Covered: EGFR Inhibitors, Angiogenesis Inhibitors, Proapoptotic Agents, mTor/Map kinase/Signal Transduction/Akt, Novel Cytotoxics, Vaccines/Gene Therapy, Related Disease States and Radiation Therapy

Conference Objectives: After attending this activity, participants should be able to:

Assess the efficacy of novel targeted-agent–based regimens currently under investigation for the treatment of your patients with lung cancer.
Assess the results from recent studies aimed at identifying markers and patient characteristics predictive of response to specific therapeutic agents.
Identify the critical factors for designing rational combinations with targeted agents for your patients with NSCLC .
Describe the efficacy and safety of novel radiation techniques and regimens under investigation for the treatment of your patients with lung cancer.
Based on the results of recent clinical trials, compare the risks and benefits of novel regimens for the second-line treatment of your patients with NSCLC.

Who Should Attend: The target audience will include medical and radiation oncologists, pathologists, community practitioners, researchers, fellows, and junior faculty involved in the diagnosis and management of patients with thoracic malignancies.

Registration Information: www.thecbce.com/currentactivities.asp

Conference Fees: Physician (in practice or academic research): $195. Fellow (with letter of fellow status from director): complimentary. Industry/All others: $1,895 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)

Continuing Education: Yes